Looking toward basic science for potential drug discovery targets against community-associated MRSA

Medicinal Research Reviews

Volumn 30, Issue 1, 2010, Pages 1-22

  Otto, Michael ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibiotic resistance; Community associated methicillin resistant Staphylococcus aureus; Virulence

Indexed keywords

ALPHA TOXIN; ANTIBIOTIC AGENT; ANTITOXIN; BACTERIAL VACCINE; BACTERIOCIN; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; ORITAVANCIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN G; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; DRUG SYNTHESIS; HOSPITAL INFECTION; HUMAN; INNATE IMMUNITY; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NECROTIZING FASCIITIS; NEUROPATHY; NONHUMAN; PATHOGENESIS; REVIEW; SEPSIS; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TOXIC SHOCK SYNDROME;

BIOFILMS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE OUTBREAKS; HUMANS; IMMUNE EVASION; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; UNITED STATES; VIRULENCE;

EID: 72549099937     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20160     Document Type: Review

References (128)

1. Barber M, Rozwadowska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet 1948;2:641-644.
2. Kirby WM. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 1944;99:452-453.
3. Stewart GT, Holt RJ. Evolution of natural resistance to the newer penicillins. Br Med J 1963;1:308-311.
4. CDC. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. Jama 1999;282:1123-1125.
5. CDC. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003;52:88.
6. Alksne LE, Projan SJ. Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 2000;11:625-636.
7. Kloos W, Schleifer KH. Staphylococcus. In: Sneath PHA, Mair S, Sharpe ME, Holt JG, editors. Bergey's manual of systematic bacteriology. Baltimore: Williams & Wilkins; 1986.
8. Schleifer KH, Kocur M. Classification of staphylococci based on chemical and biochemical properties. Arch Mikrobiol 1973;93:65-85.
9. Kluytmans JA, Mouton JW, Ijzerman EP, Vandenbroucke-Grauls CM, Maat AW, Wagenvoort JH, Verbrugh HA. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995;171:216-219.
10. Williams RE. Healthy carriage of Staphylococcus aureus: Its prevalence and importance. Bacteriol Rev 1963;27:56-71.
11. Brook I. Bacterial interference. Crit Rev Microbiol 1999;25:155-172.
12. Goerke C, Kummel M, Dietz K, Wolz C. Evaluation of intraspecies interference due to agr polymorphism in Staphylococcus aureus during infection and colonization. J Infect Dis 2003;188:250-256. (Pubitemid 36898157)
13. Lina G, Boutite F, Tristan A, Bes M, Etienne J, Vandenesch F. Bacterial competition for human nasal cavity colonization: Role of Staphylococcal agr alleles. Appl Environ Microbiol 2003;69:18-23.
14. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-532.
15. Novick RP. Mobile genetic elements and bacterial toxinoses: The superantigen-encoding pathogenicity islands of Staphylococcus aureus. Plasmid 2003;49:93-105.
16. Kass EH, Parsonnet J. On the pathogenesis of toxic shock syndrome. Rev Infect Dis 1987;9:S482-S489.
17. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990;17:251-272.
18. Anonymous. National Nosocomial Surveillance System Report. Atlanta, GA: Center for Disease Control and Prevention, US Department for Health and Human Services; 1998.
19. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13-24.
20. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284:1318-1322.
21. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol 2008;322:207-228.
22. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994;48:585-617.
23. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998;6:484-488.
24. Jefferson KK. What drives bacteria to produce a biofilm? FEMS Microbiol Lett 2004;236:163-173.
25. Otto M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol 2006;306:251-258. (Pubitemid 47400325)
26. Rice KC, Mann EE, Endres JL, Weiss EC, Cassat JE, Smeltzer MS, Bayles KW. The cidA murein hydrolase regulator contributes to DNA release and biofilm development in Staphylococcus aureus. Proc Natl Acad Sci USA 2007;104:8113-8118.
27. Mack D, Fischer W, Krokotsch A, Leopold K, Hartmann R, Egge H, Laufs R. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: Purification and structural analysis. J Bacteriol 1996;178:175-183.
28. Vuong C, Voyich JM, Fischer ER, Braughton KR, Whitney AR, DeLeo FR, Otto M. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol 2004;6:269-275. (Pubitemid 38248010)
29. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001;413:860-864. (Pubitemid 33026855)
30. Yao Y, Sturdevant DE, Otto M. Genomewide analysis of gene expression in Staphylococcus epidermidis biofilms: Insights into the pathophysiology of S. epidermidis biofilms and the role of phenol-soluble modulins in formation of biofilms. J Infect Dis 2005;191:289-298.
31. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005;3:948-958.
32. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004;199:687-695.
33. Chavakis T, Hussain M, Kanse SM, Peters G, Bretzel RG, Flock JI, Herrmann M, Preissner KT. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med 2002;8:687-693.
34. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004;17:218-234.
35. Begun J, Gaiani JM, Rohde H, Mack D, Calderwood SB, Ausubel FM, Sifri CD. Staphylococcal biofilm exopolysaccharide protects against Caenorhabditis elegans immune defenses. PLoS Pathog 2007;3:e57.
36. Peterson PK, Quie PG, Kim Y, Wilkinson BJ, Verbrugh HA, Verhoef J. Recognition of Staphylococcus aureus by human phagocytes. Signals and disguises of the bacterial surface. Scand J Infect Dis Suppl 1983;41:67-78.
37. Forsgren A, Nordstrom K. Protein A from Staphylococcus aureus: The biological significance of its reaction with IgG. Ann N Y Acad Sci 1974;236:252-266.
38. Jongerius I, Kohl J, Pandey MK, Ruyken M, van Kessel KP, van Strijp JA, Rooijakkers SH. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 2007;204:2461-2471. (Pubitemid 47529330)
39. Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, Golda A, Maciag-Gudowska A, Brix K, Shaw L, Foster T, Potempa J. A potential new pathway for Staphylococcus aureus dissemination: The silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS ONE 2008;3:e1409.
40. Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006;4:529-536. (Pubitemid 43905612)
41. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003;5:1317-1327.
42. Harder J, Schroder JM. Antimicrobial peptides in human skin. Chem Immunol Allergy 2005;86:22-41.
43. Peschel A. How do bacteria resist human antimicrobial peptides? Trends Microbiol 2002;10:179-186.
44. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol 2007;66:1136-1147. (Pubitemid 350115022)
45. Li M, Lai Y, Villaruz AE, Cha DJ, Sturdevant DE, Otto M. Gram-positive three-component antimicrobial peptide-sensing system. Proc Natl Acad Sci USsA 2007;104:9469-9474. (Pubitemid 47185803)
46. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000;13:16-34, table of contents.
47. Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991;55:733-751.
48. Valeva A, Walev I, Pinkernell M, Walker B, Bayley H, Palmer M, Bhakdi S. Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not in resistant cells. Proc Natl Acad Sci USA 1997;94:11607-11611.
49. Liang X, Ji Y. Alpha-toxin interferes with integrin-mediated adhesion and internalization of Staphylococcus aureus by epithelial cells. Cell Microbiol 2006;8:1656-1668. (Pubitemid 44350024)
50. Szmigielski S, Prevost G, Monteil H, Colin DA, Jeljaszewicz J. Leukocidal toxins of staphylococci. Zentralbl Bakteriol 1999;289:185-201.
51. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1510-1514.
52. Mellor IR, Thomas DH, Sansom MS. Properties of ion channels formed by Staphylococcus aureus delta-toxin. Biochim Biophys Acta 1988;942:280-294.
53. van Belkum A, Melles DC, Nouwen J, van Leeuwen WB, van Wamel W, Vos MC, Wertheim HF, Verbrugh HA. Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. Infect Genet Evol 2008.
54. van Belkum A, Emonts M, Wertheim H, de Jongh C, Nouwen J, Bartels H, Cole A, Cole A, Hermans P, Boelens H, Toom NL, Snijders S, Verbrugh H, van Leeuwen W. The role of human innate immune factors in nasal colonization by Staphylococcus aureus. Microbes Infect 2007;9:1471-1477.
55. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001;344:11-16. (Pubitemid 32064839)
56. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004;364:703-705.
57. Wertheim HF, Walsh E, Choudhurry R, Melles DC, Boelens HA, Miajlovic H, Verbrugh HA, Foster T, van Belkum A. Key role for clumping factor B in Staphylococcus aureus nasal colonization of humans. PLoS Med 2008;5:e17.
58. Fraser I. Penicillin: early trials in war casualties. Br Med J (Clin Res Ed) 1984;289:1723-1725.
59. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003;111:1265-1273. (Pubitemid 36554694)
60. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updat 1998;1:135-150.
61. Goldrick B. First reported case of VRSA in the United States. Am J Nurs 2002;102:17.
62. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-674.
63. Noto MJ, Fox PM, Archer GL. Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1221-1229.
64. Jevons MP, Parker MT. The evolution of new hospital strains of Staphylococcus aureus. J Clin Pathol 1964;17:243-250.
65. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama 2007;298:1763-1771.
66. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001;9:486-493.
67. Ender M, McCallum N, Adhikari R, Berger-Bachi B. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:2295-2297. (Pubitemid 38691635)
68. Lee SM, Ender M, Adhikari R, Smith JM, Berger-Bachi B, Cook GM. Fitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous culture. Antimicrob Agents Chemother 2007;51:1497-1499. (Pubitemid 46586836)
69. Hanssen AM, Kjeldsen G, Sollid JU. Local variants of Staphylococcal cassette chromosome mec in sporadic methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococci: Evidence of horizontal gene transfer? Antimicrob Agents Chemother 2004;48:285-296.
70. Chambers HF. Community-associated MRSA - resistance and virulence converge. N Engl J Med 2005;352:1485-1487.
71. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. J Am Med Assoc 1998;279:593-598. (Pubitemid 28110205)
72. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674. (Pubitemid 44244537)
73. CDC. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
74. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005;41:S269-S272.
75. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-1453.
76. Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle-Vavra S, Daum RS. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005;353:1245-1251. (Pubitemid 41345946)
77. Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol 2008;16:361-369.
78. Witte W, Strommenger B, Cuny C, Heuck D, Nuebel U. Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J Antimicrob Chemother 2007;60:1258-1263.
79. Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:309-317.
80. Murray RJ. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J 2005;35:S106-S119. (Pubitemid 44933544)
81. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Said-Salim B, Porcella SF, Long RD, Dorward DW, Gardner DJ, Kreiswirth BN, Musser JM, DeLeo FR. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 2005;175:3907-3919.
82. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang XG, DeLeo FR, Chambers HF, Lu Y, Otto M. Evolution of virulence in epidemic community-associated MRSA. Proc Natl Acad Sci USA 2009;106:5883-5888.
83. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-984. (Pubitemid 36944519)
84. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-759.
85. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS ONE 2008;3:e3198.
86. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194:1761-1770.
87. Wardenburg JB, Bae T, OttoM, DeLeo FR, Schneewind O. Poring over pores: Alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007;13:1405-1406. (Pubitemid 350224232)
88. Wardenburg JB, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus Disease. J Infect Dis 2008;198:1166-1170.
89. Montgomery CP, Daum RS. Transcription of inflammatory genes in the lung after infection with community-associated methicillin-resistant Staphylococcus aureus: A role for Panton-Valentine leukocidin? Infect Immun 2009, Epub.
90. Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, Bowden MG. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 2009;15:156-164.
91. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Hook M, Etienne J, Vandenesch F, Bowden MG. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007;315:1130-1133. (Pubitemid 46328024)
92. Villaruz A, Bubeck Wardenburg J, Khan BA, Whitney AR, Sturdevant DE, Gardner DJ, DeLeo FR, Otto M. A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J Infect Dis 2009, in press.
93. Woodin A. Staphylococcal leukocidin. In: Montje T, Kadis S, Ajl S, editors. Microbial toxins. Vol.3. New York: Academic Press, Inc.; 1970. pp 327-355.
94. Wardenburg JB, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008.
95. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, Sensabaugh GF, Perdreau-Remington F. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006;367:731-739. (Pubitemid 43326291)
96. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: Convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 2008;197:1523-1530.
97. McBride D. CA-MRSA lesions: What works, what doesn't. J Fam Pract 2008;57:588-592.
98. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol 1995;49:711-745.
99. Kennedy AD, Otto M, Braughton KR, Whitney AR, Chen L, Mathema B, Mediavilla JR, Byrne KA, Parkins LD, Tenover FC, Kreiswirth BN, Musser JM, DeLeo FR. Epidemic community-associated methicillin-resistant Staphylococcus aureus: Recent clonal expansion and diversification. Proc Natl Acad Sci USA 2008;105:1327-1332.
100. Traber KE, Lee E, Benson S, Corrigan R, Cantera M, Shopsin B, Novick RP. agr function in clinical Staphylococcus aureus isolates. Microbiology 2008;154:2265-2274.
101. Vuong C, Saenz HL, Gotz F, Otto M. Impact of the agr quorum-sensing system on adherence to polystyrene in Staphylococcus aureus. J Infect Dis 2000;182:1688-1693. (Pubitemid 30951791)
102. Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister S, Anderson J, Jensen B, Dodson D, Lonsway D, McDougal LK, Arduino M, Fraser VJ, Killgore G, Tenover FC, Cody S, Jernigan DB. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-475. (Pubitemid 40175973)
103. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Haivan Phan T, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008;148:249-257. (Pubitemid 351665484)
104. Vara Prasad JV. New oxazolidinones. Curr Opin Microbiol 2007;10:454-460.
105. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: Effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007;8:2381-2400. (Pubitemid 350017285)
106. Weis F, Beiras-Fernandez A, Schelling G. Daptomycin, a lipopeptide antibiotic in clinical practice. Curr Opin Investig Drugs 2008;9:879-884.
107. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KP, van Strijp JA. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001;193:1067-1076.
108. Hachmann AB, Angert ER, Helmann JD. Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrob Agents Chemother 2009;53:1598-1609.
109. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1079-1082. (Pubitemid 43327815)
110. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006;43:518-524.
111. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46:S368-S377.
112. Otto M. Targeted immunotherapy for staphylococcal infections: Focus on anti-MSCRAMM antibodies. BioDrugs 2008;22:27-36.
113. Jensen K. A normally occurring Staphylococcus antibody in human serum. Acta Pathol Microbiol Scand 1958;44:421-428.
114. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-496. (Pubitemid 34441740)
115. DeLeo FR, Otto M. An antidote for Staphylococcus aureus pneumonia? J Exp Med 2008;205:271-274.
116. Projan SJ, Nesin M, Dunman PM. Staphylococcal vaccines and immunotherapy: To dream the impossible dream? Curr Opin Pharmacol 2006;6:473-479.
117. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006;103:16942-16947.
118. Wang L, Barrett JF. Control and prevention of MRSA infections. Methods Mol Biol 2007;391:209-225.
119. Vos MC, Ott A, Verbrugh HA. Successful search-and-destroy policy for methicillin-resistant Staphylococcus aureus in The Netherlands. J Clin Microbiol 2005;43:2034; author reply 2034-2035.
120. Ellis MW, Griffith ME, Dooley DP, McLean JC, Jorgensen JH, Patterson JE, Davis KA, Hawley JS, Regules JA, Rivard RG, Gray PJ, Ceremuga JM, Dejoseph MA, Hospenthal DR. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: A cluster randomized controlled trial. Antimicrob Agents Chemother 2007;51:3591-3598. (Pubitemid 47519348)
121. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002;39:337-341.
122. Otto M. Antibodies to block staph virulence. Chem Biol 2007;14:1093-1094.
123. Otto M. Quorum-sensing control in Staphylococci-a target for antimicrobial drug therapy? FEMS Microbiol Lett 2004;241:135-141.
124. Lyon GJ, Mayville P, Muir TW, Novick RP. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. Proc Natl Acad Sci USA 2000;97:13330-13335.
125. Ji G, Beavis R, Novick RP. Bacterial interference caused by autoinducing peptide variants. Science 1997;276:2027-2030.
126. Park J, Jagasia R, Kaufmann GF, Mathison JC, Ruiz DI, Moss JA, Meijler MM, Ulevitch RJ, Janda KD. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 2007.
127. Montgomery CP, Boyle-Vavra S, Adem PV, Lee JC, Husain AN, Clasen J, Daum RS. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008;198:561-570.
128. Sakoulas G, Eliopoulos GM, Moellering Jr RC, Wennersten C, Venkataraman L, Novick RP, Gold HS. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002;46:1492-1502. (Pubitemid 34415333)